Impact of the new Beckman Coulter Cytomics FC 500 5-color flow cytometer on a regional flow cytometry clinical laboratory service.
暂无分享,去创建一个
[1] A. Órfão,et al. The "ex vivo" patterns of CD2/CD7, CD57/CD11c, CD38/CD11b, CD45RA/CD45RO, and CD11a/HLA-DR expression identify acute/early and chronic/late NK-cell activation states. , 2002, Blood cells, molecules & diseases.
[2] A Truchaud,et al. New tools for laboratory design and management. , 1997, Clinical chemistry.
[3] A. Borkhardt,et al. Infant acute lymphoblastic leukemia – combined cytogenetic, immunophenotypical and molecular analysis of 77 cases , 2002, Leukemia.
[4] A Orfao,et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation , 2002, Leukemia.
[5] Michael N Dworzak,et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. , 2002, Blood.
[6] A. Órfão,et al. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. , 2001, Cytometry.
[7] N. Villamor,et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells , 2003, Leukemia.
[8] S. Baudet,et al. Novel flow‐cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia , 2002, British journal of haematology.
[9] R. Foà,et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T‐cell acute lymphoblastic leukaemia , 2003, British journal of haematology.
[10] A. Órfão,et al. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML). , 2002, Best practice & research. Clinical haematology.
[11] A. Órfão,et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. , 2000, Journal of immunological methods.
[12] E. Matutes,et al. New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. , 2002, Journal of clinical pathology.
[13] S. A. Whalen,et al. Laboratory automation: trajectory, technology, and tactics. , 2000, Clinical chemistry.
[14] J. Mazur,et al. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia , 2003, Leukemia.
[15] C. Bloomfield,et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). , 2001, Blood.